^
Association details:
Biomarker:TSC2 mutation
Cancer:Renal Cell Carcinoma
Drug Class:mTOR inhibitor
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

Comprehensive molecular and immunohistochemical analysis of advanced renal cell carcinoma patients treated with mTOR inhibitors.

Published date:
05/16/2018
Excerpt:
TSC1, TSC2 and MTOR mutations only partially correlated with response. Lack of BAP1 and PBRM1 expression was associated with improved response to mTOR inhibitors.
DOI:
10.1200/JCO.2018.36.15_suppl.4559